Understanding Cannabis Addiction: Mechanisms, Withdrawal, and Treatment Targets | Research

The takeaway

A comprehensive review of cannabinoid abuse mechanisms found that while no approved medications exist for cannabis use disorder, several molecular targets including FAAH inhibitors and allosteric CB1 modulators show promise in preclinical models.

Read this if you struggle with cannabis dependence and want to understand the neuroscience or are interested in treatment development.

Zero approved medications for cannabis use disorder as of 2015

What the researchers found

This review synthesized research on the mechanisms of cannabinoid abuse, withdrawal, and relapse from both human and animal studies.

The review described how cannabinoids produce rewarding effects through CB1 receptor activation in the brain's reward circuitry, how tolerance develops through receptor downregulation, and how withdrawal symptoms emerge when chronic stimulation stops. Cannabis withdrawal includes irritability, anxiety, sleep disturbance, and decreased appetite.

Several potential pharmacotherapy targets were identified: FAAH inhibitors (which boost endocannabinoid levels), allosteric modulators of CB1 receptors, and medications targeting overlapping neurotransmitter systems. However, no approved treatments existed at the time of publication.

Why it matters

Cannabis use disorder affects millions of people worldwide, yet there are no FDA-approved medications for treatment. Understanding the neurobiology of cannabis addiction is essential for developing targeted treatments.

The numbers in context

No approved medications for cannabis use disorder; potential targets reviewed: FAAH inhibitors, allosteric CB1 modulators, GABAergic agents, and others

How the study worked

Comprehensive review of preclinical and clinical research on cannabinoid abuse, covering reward mechanisms, adverse effects, withdrawal, relapse, and potential pharmacotherapies.

What this study cannot tell us

Many promising pharmacological targets had only preclinical support at the time. Animal models of cannabis reward and relapse may not fully capture human addiction. The review acknowledged that most candidate medications face significant development hurdles.

How to read the evidence

Comprehensive review in a major pharmacology journal, synthesizing human and animal research. Individual treatment targets had varying levels of evidence.

When this study was published

Published in 2015. Several clinical trials of potential cannabis addiction medications have since been conducted.

The bigger picture

As cannabis potency increases and access expands, the number of people developing cannabis use disorder is likely to grow. The development of effective pharmacotherapies is increasingly urgent.

Questions still open

Which pharmacological targets will prove most effective in human clinical trials? Can combination therapies improve outcomes? Would different medications work better for different aspects of cannabis addiction (withdrawal vs. craving vs. relapse)?

Common questions

Can you get addicted to cannabis?

Yes. Cannabis use disorder is a recognized clinical condition. This review described the neurobiological mechanisms: CB1 receptor activation in reward circuits, tolerance through receptor changes, and withdrawal symptoms when chronic use stops.

Are there medications for cannabis addiction?

As of this 2015 review, no medications were approved for cannabis use disorder. Several targets showed promise in preclinical research, including FAAH inhibitors and CB1 receptor modulators, but none had completed clinical development.

Read the original research

Cannabinoid abuse and addiction: Clinical and preclinical findings.

Clinical pharmacology and therapeutics, 97(6), 616-27

View on PubMed ↗Publisher’s paper ↗

Citation

Panlilio, L V; Goldberg, S R; Justinova, Z. (2015). Cannabinoid abuse and addiction: Clinical and preclinical findings.. Clinical pharmacology and therapeutics, 97(6), 616-27. https://doi.org/10.1002/cpt.118